Moderna, mRNA and bird flu

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.
Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.
Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.
We recently compiled a list of the These 10 Companies Led Gains on Wednesday. In this article, we are going to take a look at ...
Moderna shares closed up Thursday gaining momentum following recent comments by Oracle Chairman Larry Ellison about the role of artificial intelligence in revolutionizing cancer treatment.
Moderna stock has fallen over the past four years, but shares got a boost on positive comments about AI. Is MRNA stock a buy ...